
Opinion|Videos|July 19, 2024
EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma
Author(s)Joseph Mikhael, MD
Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.
Advertisement
Video content above is prompted by the following question:
- Discuss the data presented at EHA 2024 on the efficacy and safety of teclistimab in patients with relapsed/refractory multiple myeloma (RRMM) with high-risk features: a subgroup analysis of the phase 1/2 MajesTEC-1 study. (Abstract)
- What was the objective of the subgroup analysis of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- N=165
- N=24 aged ≥75 years
- N=20 ISS stage III
- N=38 high-risk cytogenetics
- N=28 extramedullary disease
- N=18 bone marrow plasma cells
- N=50 penta-drug refractory
- Median follow up ~30 months across subgroups
- Objective Response Rate (ORR)
- Median duration of response (mDOR)
- Safety
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5